- Affimed N.V. ( NASDAQ: AFMD ) is trading 2.5% higher premarket after it said on Thursday the French National Agency for the Safety of Medicines and Health Products had approved a clinical trial application for the phase 1 study of AFM28 in relapsed/refractory acute myeloid leukemia.
- The company has filed applications to begin trial for AFM28-101 in other European jurisdictions as well, and additional applications are planned for submission in early 2023.
- ( AFMD ) also plans to investigate AFM28 in combination with allogenic natural killer (NK) cell therapy
For further details see:
Affimed receives approval to begin human trial for acute myeloid leukemia therapy in France